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One of the most exciting challenges in rheumatology for 
the future is to ﬁ  nd a therapeutic target for osteoarthritis 
(OA) [1]. Indeed, clinicians and our patients are still 
waiting for a new drug that exhibits an analgesic eﬀ  ect 
and structure-modulating properties.
OA is characterised by an imbalance between catabolic 
and anabolic responses of stimulated chondrocytes, 
driven locally by a soup of cytokines where IL-1β is 
regarded as the chief orchestrator. On the one hand, IL-1 
can induce the production of enzymes, prostanoids, 
nitric oxide and free radicals; on the other hand, IL-1 can 
block the production of collagen type 2 and proteoglycans 
[2,3]. IL-1 is also involved in the transmission of pain [4]. 
Considering all these factors, targeting IL-1 in OA seems 
a logical approach to slow down the disease progression.
In diﬀ   erent animal models, Martel-Pelletier and 
colleagues were the ﬁ  rst to use IL-1 receptor antagonist 
(IL-1ra) injected intraarticularly – either directly or 
through gene therapy – with encouraging results in terms 
of cartilage preservation [5]. Moreover, in patients with 
rheumatoid arthritis, anakinra (IL-1ra) injected 
subcutaneously daily demonstrates a disease-modifying 
antirheumatic eﬀ  ect [6].
In this context, we performed two trials with one single 
intraarticular injection of IL-1ra in knee OA [7,8]. Th  e 
main result of the randomised, placebo-controlled trial 
using two doses of IL-1ra (50 mg and 150 mg) was 
negative regarding the evolution of pain after a follow-up 
of 3 months [8]. However, diﬀ   erent hypotheses could 
possibly explain this negative result: the short half-life of 
IL-1ra, the single intraarticular injection, or the excess of 
IL-1ra already present in the synovial ﬂ  uid.
Th   e contribution of Cohen and colleagues, published in 
the present issue of Arthritis Research & Th  erapy, is 
there  fore a major contribution to enlighten the anti-IL-1 
strategy in OA [1]. Th  e authors use systemic adminis-
tration of a monoclonal antibody (AMG 108) directed 
against the functional type 1 receptor of IL-1. Th  is is a 
two-part randomised, double-blind, placebo-controlled, 
multiple-dose study in patients with OA. Th  e most 
interesting part of the study is the second, in which 
patients received 300 mg AMG 108 subcutaneously once 
every 4 or 12 weeks compared with placebo. Th  ere are 
two major conclusions that could be drawn from this 
study: one on eﬃ   cacy, and one on safety. Th  e  main  end-
point was the level of pain at 6 weeks and no statistical 
diﬀ   erence with placebo was observed. Furthermore, 
AMG 108 induced a decrease in neutrophil count and, 
while the incidence of serious infections was similar in 
the AMG 108 and placebo groups, a death in this trial 
might be indirectly related to neutropaenia in an 80-year-
old man and may lead to suspension of the programme.
Regarding this negative trial, should we deﬁ  nitively put 
nails in the coﬃ   n of an anti-IL-1 option in OA?
Looking at the beneﬁ  t/risk ratio in the study by Cohen 
and colleagues, it is tempting to answer yes. However, we 
should probably bring some reservations to this opinion.
First, there is a real trend of eﬃ   cacy favouring AMG 
108 compared with placebo, especially in patients with a 
high level of pain at baseline (Western Ontario and 
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Blocking IL-1 in patients with knee osteoarthritis is 
an attractive strategy. Cohen and colleagues report a 
randomised, placebo-controlled, multiple-dose trial 
using a monoclonal antibody blocking IL-1 type 1 
receptor. They failed to show any positive results in 
terms of evolution of pain for up to 12 weeks, in line 
with the former trials using intraarticular injections 
of IL-1 receptor antagonist. A trend was observed, 
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pain at baseline. Although these data may suggest 
cessation of IL-1 therapy in osteoarthritis, other 
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may be linked to the small number of patients in this 
subgroup (n = 22 AMG 108-treated patients and n = 25 
placebo-treated patients), which may subsequently 
contribute to the overall negative result. Similarly, 
signiﬁ  cant  eﬃ     cacy was observed in the randomised, 
placebo-controlled trial with one single intraarticular 
injection of IL-1ra (150 mg) compared with placebo at 
day 4, suggesting some real but unstained clinical beneﬁ  t 
[8]. Interestingly, ultra  sensitive C-reactive protein levels 
decreased with anti-IL-1 therapy [1]. C-reactive protein 
is a relevant marker in OA related to tibial cartilage 
volume and local inﬂ  ammation, and is a good prognostic 
marker of disease progression [9,10]. Th  e question of 
chondro  protection by anti-IL-1 therapy is still so far 
unanswered, although some preliminary results with 
magnetic resonance imaging indicate improvement of 
synovial membrane inﬂ   ammation [8]. Th  e nonlinear 
nature of the pharmacokinetics may also contribute to 
variations in the local concentration of AMG 108 in the 
synovial ﬂ  uid (calculated to be around 50 nM) [1]. Th  e 
remain  ing question is whether this concentration is able 
to block IL-1 activity not only in the synovial ﬂ  uid but 
also in the superﬁ  cial cartilage layers.
Th   e other conclusion concerns safety. What we can learn 
from this current study is that long-term bio  therapy, which 
may expose patients to serious side eﬀ   ects, is not 
acceptable in a benign disease such as OA.
We should therefore rethink an IL-1 strategy in OA. 
One of the most appealing approaches could be the 
intraarticular route of administration with repeated 
intra  articular injections to increase the local concen  tra-
tion of the drug into the joint, especially during ﬂ  are-up 
of the disease. In doing so, we can also hope to diminish 
the risk of serious side eﬀ  ects.
For sure, the story is not ﬁ  nished.
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